Mylan Laboratories ( MYL) Monday said federal regulators had granted tentative approval to its anti-psychotic drug Risperidone. The Pennsylvania-based drugmaker said Risperidone is one of 10 potential first-to-file applications before the Food and Drug Administration. In January, Mylan reported record third-quarter net income of $84.6 million, or 31 cents a share, on revenue of almost $350 million. The company also forecast EPS of $1.11 to $1.18 for fiscal 2004 and $1.30 to $1.40 for 2005. The consensus estimates are $1.13 and $1.36 a share, respectively, according to Thomson One Analytics. Mylan said Risperidone is the generic version of Janssen Pharmaceutica's Risperdal tablets. Shares rose 20 cents, or 0.9%, to $23.54.